An anticancer sustained release agent carrying angiogenesis inhibitor and cytotoxic drug

Abstract

Disclosed is an anticancer slow release injection carrying both anti-angiogenesis agent and cytotoxic drugs, which comprises slow release micro-balloons and dissolvent, wherein the slow release microballoons comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being specific dissolvent containing suspension adjuvant. the anti-angiogenesis agent is selected from Marimastat, SU5416, SU6688, Fumagillin and / or TNP-470, the cytotoxic drugs are selected from anti-taxone, alkylating agent, Topo enzyme inhibitor and / or plant alkaloid, The slow release auxiliary materials are selected from Polifeprosan, di-aliphatic acid and sebacylic acid copolymer, poly(erucic aciddipolymer-sebacylic acid), poly(fumaric acid-sebacylic acid), ethylene-vinylacetate copolymer, the viscosity of the suspension adjuvant is 100-3000cp (at 25-30 deg C).

Description

(1) Technical field

[0001] The invention relates to a sustained-release agent carrying neovascularization inhibitors and cytotoxic drugs and a preparation method thereof, belonging to the technical field of medicines. Specifically, the present invention provides a slow-release preparation of anticancer drugs containing neovascularization inhibitors and / or cytotoxic drugs, mainly slow-release injections and slow-release implants. (2) Background technology

[0002] Angiogenesis is necessary for the growth and metastasis of solid tumors. When the diameter of solid tumor is larger than 0.5cm, tumor cells depend on their own vascular system. Tumor cells can obtain nutrients and oxygen from the host through tumor blood vessels, and can continuously transport metastatic cells to the host through tumor blood vessels, and continue to grow and induce blood vessel formation in other parts of the body, leading to tumor metastasis. The emergence of new metastases is the main reason for...